Foolish Review: Eli Lilly Earnings

In the following video, Motley Fool health care analyst David Williamson takes investors through Eli Lilly's mixed quarter. Though the company faces some big near-term difficulties owing to it stepping off a huge patent cliff this quarter, it managed to beat analysts' expectations, which drove shares up 4%. David discusses how the company was able to beat this quarter, just how much its patent cliff hurt, and what we can expect from the company this year.

Over the next two years, Eli Lilly will see nearly $0.40 of every $1.00 in sales exposed to generic competition. How does the company plan to respond to this huge patent cliff? Better yet, what does this mean for investors? In a brand new premium report on Eli Lilly, The Motley Fool's top pharmaceuticals analyst delves into everything investors need to know about the stock today. Simply click here now to claim your copy.

The article Foolish Review: Eli Lilly Earnings originally appeared on Fool.com.

David Williamson owns shares of Pfizer. Follow him on Twitter: @MotleyDavid. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.